MDCK Influenza Vaccines: Solving the Challenges of Residual DNA QC

For over seventy years, the global production of influenza vaccines has relied on a humble, everyday agricultural product: the fertilized chicken egg. While this century-old method has successfully protected millions, the biomanufacturing landscape is shifting.

Recently, the Center for Drug Evaluation (CDE) in China accepted the New Drug Application for a quadrivalent split influenza vaccine utilizing Madin-Darby Canine Kidney (MDCK) mammalian cells, submitted by the Wuhan Institute of Biological Products. Moving away from traditional embryonated eggs to a mammalian cell culture platform represents a massive industry milestone, signaling that domestic vaccine manufacturing is ready for a generational upgrade.

The 70-Year Era of the Egg: A Legacy Facing Bottlenecks

Since the 1940s, the blueprint for making flu shots has been straightforward: WHO recommends a strain, manufacturers inject it into SPF (Specific Pathogen-Free) chicken eggs, and the virus replicates inside the allantoic cavity before being harvested, inactivated, and purified.

Despite its storied history, the egg-based supply chain comes with clear limitations:

MDCK Cells: The Modern Mammalian Platform

Established back in 1958, the MDCK cell line has long served as the gold standard for laboratory influenza virus isolation. Because mammalian cells share a closer receptor profile with human respiratory tracts than avian eggs do, viruses replicate with higher fidelity and fewer adaptive mutations.

Furthermore, cells can be grown at scale inside closed bioreactors. They eliminate reliance on agricultural supply chains, remove ovalbumin risks, and allow for flexible, high-capacity manufacturing. 

This transition isn’t entirely brand-new globally—the U.S. FDA approved its first MDCK cell-cultured flu vaccine way back in 2012. However, with multiple domestic pioneers now entering the race, the local industry is fast tracking toward a dual-track future of "eggs + cells."

A new production substrate brings new quality control requirements

Switching production substrates changes more than just the vessel; it introduces a completely new set of quality control challenges.Because MDCK lines are continuous cell lines, their genetic material may carry sequences associated with tumor-forming potential. Regulatory agencies worldwide—including the WHO, USP, and ICH—enforce stringent limits on host cell residual DNA (typically keeping levels at $\le10\text{ ng/dose}$, depending on local regulations).To meet these standards, manufacturers must implement robust purification techniques capable of removing nucleic acid fragments, alongside hyper-sensitive testing protocols to monitor residual DNA across every stage—from intermediate batches to final product release.

Empowering Quality Control with Specialized Solutions-MDCK Host Cell DNA Residue Detection

To support this shift toward high-purity, scalable cell-based biologics, advanced upstream tools and QC raw materials are vital.

Solutions like Yeasen's MDCK Host Cell DNA Residue Detection Kit (Cat# 41319ES)` utilize TaqMan probe-based fluorescence quantitative PCR to quickly and accurately quantify residual DNA in biological samples. When paired with automated magnetic bead extraction options like the Cat# 18461ES/18469ES sample preparation kits and the 48-channel nucleic acid extractor, labs can streamline workflows from sample extraction to final data in under three hours.

Validated against rigorous pharmacopeia standards (ChP, USP, ICH), these robust analytical kits ensure that as vaccine developers modernize their production floors, safety and compliance remain front and center.

Product performance

Performance data

1)Standard curve linearity

The kit demonstrated a linear range of 3 fg/µL–300 pg/µL, with R² = 1 and amplification efficiency of 99.29%. The CV of measured values at each concentration was <15%.

Figure 1. MDCK DNA standard curve (left) and amplification curves across the tested concentration range (right).

2) Specificity

Genomic DNA from cell types commonly used in biological product manufacturing was tested for interference with the MDCK DNA assay. The curves for the spiked and control groups overlapped, with no observed interference. The panels below show E. coli, CHO, Vero and HEK293 genomic DNA, respectively.

Figure 2. Interference testing with E. coli , CHO, Vero and HEK293 genomic DNA.

3) Limit of quantification

MDCK DNA at 3, 1, 0.5 and 0.1 fg/µL was tested in 10 replicates per concentration. At 0.5 fg/µL and above, the CV was <20%, establishing a limit of quantification of 0.5 fg/µL for residual MDCK host cell DNA.

Figure 3. qPCR results for 0.5 fg/µL MDCK DNA. IC, internal control; M, MDCK target.

Table 1. MDCK DNA quantification at the limit of quantification.

Quality First: Securing the Transition from Eggs to Cells

Moving from chicken eggs to cell culture is more than a production update—it’s an industrial transformation. With the Wuhan Institute's filing accepted, domestic cell-based influenza vaccines have reached a critical regulatory milestone, signaling a coming wave of commercial rollouts.

However, behind every safe vaccine lie critical quality control measures, such as the precise detection of host cell residual DNA. Yeasen Biotechnology is dedicated to supporting this evolution with high-sensitivity, high-specificity residual DNA solutions like the MDCK Host Cell DNA Residue Detection Kit.

Comprehensive Bioproduct Quality Control Solutions

Yeasen offers an extensive quality control product portfolio covering gene therapy, cell therapy, mRNA, antibody drugs, and vaccines. Covering host nucleic acids, residual proteins, process impurities, microbial contaminants, and cell characterization, our solutions deliver robust support for biopharma developers from early-stage R&D to commercialization.

Related Product